Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort
Dalton C Wamalwa, Elizabeth M Obimbo, Carey Farquhar, Barbra A Richardson, Dorothy A Mbori-Ngacha, Irene Inwani, Sara Benki-Nugent, Grace John-Stewart, Dalton C Wamalwa, Elizabeth M Obimbo, Carey Farquhar, Barbra A Richardson, Dorothy A Mbori-Ngacha, Irene Inwani, Sara Benki-Nugent, Grace John-Stewart
Abstract
Background: Among children, early mortality following highly active antiretroviral therapy (HAART) remains high. It is important to define correlates of mortality in order to improve outcome.
Methods: HIV-1-infected children aged 18 months-12 years were followed up at Kenyatta National Hospital, Nairobi after initiating NNRTI-based HAART. Cofactors for mortality were determined using multivariate Cox regression models.
Results: Between August 2004 and November 2008, 149 children were initiated on HAART of whom 135 were followed for a total of 238 child-years (median 21 months) after HAART initiation. Baseline median CD4% was 6.8% and median HIV-1-RNA was 5.98-log10 copies/ml. Twenty children (13.4%) died at a median of 35 days post-HAART initiation. Mortality during the entire follow-up period was 8.4 deaths per 100 child-years (46 deaths/100 child-years in first 4 months and 1.0 deaths/100 child-years after 4 months post-HAART initiation). On univariate Cox regression, baseline hemoglobin (Hb) <9 g/dl, weight-for-height z-score (WHZ) < -2, and WHO clinical stage 4 were associated with increased risk of death (Hb <9 g/dl HR 3.00 [95% C.I. 1.21-7.39], p = 0.02, WHZ < -2 HR 3.41 [95% C.I. 1.28-9.08], p = 0.01, and WHO clinical stage 4, HR 3.08 [1.17-8.12], p = 0.02). On multivariate analysis Hb < 9 g/dl remained predictive of mortality after controlling for age, baseline CD4%, WHO clinical stage and weight-for-height z-score (HR 2.95 (95% C.I. 1.04-8.35) p = 0.04).
Conclusion: High early mortality was observed in this cohort of Kenyan children receiving HAART, and low baseline hemoglobin was an independent risk factor for death.
Figures
References
- UNAIDS 2008 Report on the Global AIDS Epidemic.
- National AIDS and STI Control Programme, Ministry of Health Kenya.
- Reddi A, Leeper SC, Grobler AC. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13. doi: 10.1186/1471-2431-7-13.
- Rouet P, Fassinou P, Inwoley A. Long-term survival and immune-virologic response of African HIV-1 infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20(18):2315–9. doi: 10.1097/QAD.0b013e328010943b.
- Song R, Jelagat J, Dzombo D. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pedaitrics. 2007;120(4):e856–61. doi: 10.1542/peds.2006-1122.
- Wamalwa D, Farquhar C, Obimbo E. Early response to highly active antiretroviral therapies among HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311–317.
- Puthanakit T, Oberdorfer A, Akarathum N. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41(1):100–7. doi: 10.1086/430714.
- Bolton-Moore C, Mubiana-Mbewe M, Cantrell J. Clinical outcomes and CD4 response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298(16):1888–1899. doi: 10.1001/jama.298.16.1888.
- Bong Chin-Nam, Yu Kwong-Leung J, Chiang H. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral therapy in a central hospital in Malawi. AIDS. 2007;21:1805–18. doi: 10.1097/QAD.0b013e3282c3a9e4.
- Gortmaker SL, Hughes M, Cervia J. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522–8. doi: 10.1056/NEJMoa011157.
- Gibb DM, Duong T, Tookey PA. Decline in mortality, AIDS and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019–24. doi: 10.1136/bmj.327.7422.1019.
- Viani R, Araneta M, Deville J. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:725–31. doi: 10.1086/423178.
- Peacock-Villada E, Richardson B, John-Stewart G. Paediatric HAART treatment outcomes: A comparison of developing and developed countries. 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009), Montreal, Canada, February 8-11 2009. Abstract 875.
- Violari A, Cotton M, Gibb D. Early Antiretroviral Therapy and Mortality among HIV-1 infected Infants. N Engl J Med. 2008;359:2233–44. doi: 10.1056/NEJMoa0800971.
- World Health Organization. Guidelines for the use of Antiretroviral Agents in Paediatrics. World Health Organization Geneva; 2009.
- National AIDS and STI Control program (NASCOP) Guideline for antiretroviral therapy in Kenya. Third. Ministry of health, Government of Kenya, Nairobi Kenya; 2005.
- World Health Organization. Management of severe malnutrition: a manual for physicians and other senior health workers. World Health Organization Geneva; 1999.
- Lutter CK. Iron deficiency in young children in low income countries and new approaches for its prevention, a review. J Nutri. 2008;138:2523–2528. doi: 10.3945/jn.108.095406.
- Monitoring the Situation of Children and Women, Statistics by Country, Kenya.
- Obimbo E, Mbori-Ngacha DA, Ochieng J. Predictors of early mortality in a cohort of Human Immunodeficiency Virus Type-1 infected African children. Pediatr Infect Dis J. 2004;23:536–543. doi: 10.1097/01.inf.0000129692.42964.30.
- Moore RD. Human immunodeficiency virus infection, Anemia and survival. Clin Infect Dis. 1999;29:44–49. doi: 10.1086/520178.
- Consolini R, Benviclli W, Legino A. Pre HAART follow-up study of the hematological manifestation in children with prenatal HIV infection, suggestions for reclassification of clinical disease. Italian register for HIV infection in children Pediatr Hematol Oncol. 2007;29:376–383.
- Kenya Demographic Health Survey. Central Bureau of Statistics, Nairobi Kenya; 2003.
- Marazzi M, Liotta G, Germano P. Excessive Early Mortality in the First Year of Treatment in HIV Type 1-Infected Patients Initiating Antiretroviral Therapy in Resource-Limited Settings. AIDS Res and Hum Retro. 2008;24:555–60. doi: 10.1089/aid.2007.0217.
- McMurray DN. Cell-mediated immunity in nutritional deficiency. Prog Food Nutr Sci. 1984;8(3-4):193–228.
- Najera O, Gonzalez, Cortes E. Effector T lymphocytes in well-nourished and malnourished infected children. Clin Exp Immunol. 2007;148(3):501–6.
- Najera O, Najera O, Gonzalez, Toledo. Flow cytometry study of lymphocytes in malnourished and well-nourished children with bacterial infections. Clin Diag Lab Immunol. 2004;11(3):577–80.
- Fassinou P, Elenga N, Rouet F. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18:1905–13. doi: 10.1097/00002030-200409240-00006.
- Smith K, Kuhn L, Coovadia. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009;23:1097–1107. doi: 10.1097/QAD.0b013e32832afefc.
- Pairoj R, Wongpraparut, Jacobs LE. Cardiac Manifestations of Acquired Immunodeficiency Syndrome. Arch Intern Med. 2000;160:602–608. doi: 10.1001/archinte.160.5.602.
- Dau B, Holodniy M. The relationship between HIV infection and Cardiovascular disease. Curr Cardiol Rev. 2008;4:203–218. doi: 10.2174/157340308785160589.
- Martinez E, Larrousse M, Gatell J. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis. 2009;22:28–34. doi: 10.1097/QCO.0b013e328320a849.
- World Health Organization, Geneva Switzerland. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. World Health Organization, Geneva; 2006.
Source: PubMed